Amy McGorry

Amy McGorry is a physical therapist and a health writer for Fox News Digital. She has made significant contributions to the field of health by providing insightful articles on various medical topics. Her work focuses on translating complex medical information into easily understandable content for the general public. With her expertise in physical therapy, she often covers stories related to treatments, diseases, and advancements in healthcare technology.

Biography:  https://www.foxnews.com/person/m/amy-mcgorry

99%

The overall score is a weighted number that takes into account conflict of interest, bias, deception and other practices that undermines the credibility of the source. It is calculated as:
Analysis.OverallConflictOfInterestScore * 0.3F + Analysis.OverallBiasScore * 0.3F + Analysis.DeceptivenessScore * 0.3F + Analysis.ReadabilityScore * 0.1F

A score that takes into consideration the content for flow, interruptions with ads, and overt search engine optimization techniques that makes the content hard to understand

The Daily's Verdict

This author is known for its high journalistic standards. The author strives to maintain neutrality and transparency in its reporting, and avoids conflicts of interest. The author has a reputation for accuracy and rarely gets contradicted on major discrepancies in its reporting.

Bias

100%

Examples:

No current examples available.

Conflicts of Interest

100%

Examples:

No current examples available.

Contradictions

100%

Examples:

No current examples available.

Deceptions

100%

Examples:

No current examples available.

Recent Articles

New Drug Iqirvo Approved for Primary Biliary Cholangitis: A Look at Emerging Therapies and Unmet Needs

New Drug Iqirvo Approved for Primary Biliary Cholangitis: A Look at Emerging Therapies and Unmet Needs

Broke On: Friday, 21 June 2024 The FDA approved Iqirvo (elafibranor) for Primary Biliary Cholangitis (PBC) treatment, showing improvements in biochemical response compared to UDCA alone. Emerging therapies like next-generation PPAR agonists and Ileal bile acid transporter inhibitors (IBAT inhibitors) are promising, reducing cholestasis and improving cognitive impairment and fatigue. Experts emphasize the need for continued observation and validation through further studies.